Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab Extension Study in Moderate-to-Severe Atopic Dermatitis (ESTUARY)
NCT06407934Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Proportion of participants who maintained vIGA-AD <=2 without experiencing relapse at 24 weeks and Proportion of participants who maintain treatment response without experiencing relapse at 48 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06407934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407934.